

Sigma-Aldrich Corporation

April 29, 2010



Enabling Science to
Improve the Quality of Life

Cautionary Statement



Our presentation today will include forward looking statements relating to the Company's future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including expectations, goals, beliefs, intentions and the like regarding future sales, earnings, cash flow, share repurchases and other matters. These statements involve assumptions regarding Company operations, investments and acquisitions and conditions in the markets the Company serves. Although the Company believes its expectations are based on reasonable assumptions, such statements are subject to risks and uncertainties including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied during this review or contained in other Company communications due to, but not limited to, such factors as (1) declining global economic conditions, (2) changes in pricing and the competitive environment and the global demand for our products, (3) fluctuations in foreign currency exchange rates, (4) changes in research funding and the success of research and development activities, (5) dependence on uninterrupted manufacturing operations, (6) changes in the regulatory environment in which the Company operates, (7) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matter described in Note 10 – Income Taxes – to the Consolidated Financial Statements in the Company's Form 10-K report for the year ended December 31, 2009, (8) exposure to litigation, including product liability claims, (9) the ability to maintain adequate quality standards, (10) reliance on third party package delivery services, (11) failure to achieve planned cost reductions in global supply chain initiatives and restructuring actions, (12) an unanticipated increase in interest rates, (13) failure of planned sales initiatives in our Research and SAFC businesses, (14) other changes in the business environment in which the Company operates, and (15) the outcome of the matters described in Note 11-Contingent Liabilities and Commitments-in the Company's Form 10-K report for the year ended December 31, 2009. The Company does not undertake any obligation to publicly update the matters covered in this presentation.

With over 60% of sales denominated in currencies other than the U.S. dollar, management uses currency-adjusted growth, and believes it is useful to investors, to judge the Company's controllable, local currency performance. Organic sales growth data presented in this review is proforma data and excludes currency impacts. While we are able to report historical currency impacts after the fact, we are unable to estimate changes that may occur later in 2010 to applicable exchange rates and thus are unable to reconcile the projected non-GAAP currency adjusted internal growth rates to reported GAAP growth rates for 2010. Any significant changes in currency exchange rates would likely have a significant impact on our reported growth rates due to the volume of our sales denominated in foreign currencies.


Management reports both GAAP and adjusted sales and income comparisons to reflect what it believes are ongoing and/or comparable operating results excluding currency impacts. Management excludes this item in judging its historical performance and in assessing its expected future performance. Management also uses free cash flow, a non-GAAP measure, to judge its performance and ability to pursue opportunities that enhance shareholder value. Management believes this non-GAAP information is useful to investors as well. Reconciliations of GAAP to non-GAAP information are included in the Company's February 10, 2010 earnings release posted on its website, www.sigma-aldrich.com

Who is Sigma-Aldrich?

Delivering Value Through a Diversified Portfolio




Sigma-Aldrich (\$ Million)	
2009 Revenue	\$2,148
2009 EBITDA	\$ 592
2009 Free Cash Flow	\$ 396




Geography

- CAPLA
- Europe
- United States



Business Units

- Research Specialties
- Research Biotech
- SAFC
- Research Essentials



Markets

- Hospitals
- Pharma & Biotech
- Industrial
- Academia


Delivering strong financial performance despite a challenging economy

Who is Sigma-Aldrich?



Research Business

- **Customers**
 - Academia
 - Pharma & Biotech
 - Industrial
 - Hospitals
 - Testing Labs
- **Products**
(170,000; 48,000 Manufactured)
 - Reagents
 - Chemicals
 - Biochemicals
 - Standards
 - Lab Supplies
 - Kits




Manufacturing (SAFC)

- **Customers**
 - Pharma
 - Biotech
 - Hitech
- **Capabilities**
 - Chemical Synthesis (API's, Intermediates)
 - Isolation, Extraction, Purification
 - Fermentation
 - Assay Development
 - Media Formulation
 - Services

A Life Science company enabling researchers and manufacturers
to improve the quality of life

Markets and Global Trends

Markets



Sigma-Aldrich participates in space with significant room for growth